Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007

Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007

Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007

Warfarin-associated intraventricular hemorrhage
Neurol Res 29: 661-663, Zubkov, A.,et al, 2007

Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006

Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006

IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006

Neoplastic Meningitis
Neurologist 12:179-187, Chamberlain,M.C., 2006

Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006

Treatment With Interferon beta-1b Delays Conversion to Clinically Definite and McDonald MS in Patients With Clinically Isolated Syndromes
Neurol 67:1242-1249, Kappos,L.,et al, 2006

Magnetic Resonance Imaging and Cerebrospinal Fluid Shunt Valves
NEJM 353:1413-1414, Akbar,M.,et al, 2005

Aneurysmal Rupture Without Subarachnoid Hemorrhage: Case Series and Literature Review
Neurosurg 57:225-229, Thai,Q-A.,et al, 2005

Unusual Presentation of Neurocysticercosis: Report of Two Cases
Nepal Journal of Neuroscience 2:185-189, Gurung,G.,et al, 2005

Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005

Management of Acute Cerebellar Stroke
Arch Neurol 62:537-544, Jensen,M.B. &St. Louis,E.K., 2005

Ventriculoperitoneal Shunt in Patients with Leptomeningeal Metastasis
Neurol 64:1625-1627, Omuro,A.M.P.,et al, 2005

FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005

Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis
Arch Neurol 62:785-792, Schwid,S.R.,et al, 2005

Corpus Callosum Changes Following Shunting for Hydrocephalus: Case Report and Review of the Literature
Clin Neurology and Neurosurgery 107:351-354, Constantinescu,C.S.,et al, 2005

Neutralizing Anti-IFN-B Antibodies
Neurol 65:6-8, Giovannoni,G.&Goodman,A., 2005

Life-Threatening Acute Pancreatitis Associated with Interferon Beta-1a Treatment in Multiple Sclerosis
Neurol 65:170-171, Midgard,R.,et al, 2005

Progressive Cervical Mye lopathy Secondary to Chronic Ventriculoperitoneal CSF Overshunting
Neurol 65:171-172, Wingerchuk,D.M.,et al, 2005

Polyneuropathy Associated with Interferon Beta Treatment in Patients with Multiple Sclerosis
Neurol 65:456-458, Ekstein,D.,et al, 2005

Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005

Pregnancy Outcomes During Treatment with Interferon Beta-1a in Patients with Multiple Sclerosis
Neurol 65:802-806, Sandberg-Wollheim,M.,et al, 2005

The Reproductive Effects of Beta Interferon Therapy in Pregnancy, A longitudinal Cohort
Neurol 65:807-811,788, Boskovic,R.,et al, 2005

Intracranial Haemorrhages in French Haemophilia Patients (1991-2001): Clinical Presentation, Management and Prognosis Factors for Death
Haemophilia 11:452-458, Stieltjes,N.,et al, 2005

Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004

An Unusual Cause of Psychosis
Lancet 363:1522, Singh,S.,et al, 2004

Clinical Implications of Benign Multiple Sclerosis: A 20-Year Population-Based Follow-Up Study
Ann Neurol 56:303-306, Pittock,S.J.,et al, 2004

Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 364:1489-1496,1463, Filippi,M.,et al, 2004

Interferon beta-1b in Secondary Progressive MS
Neurol 63:1779-1787,1768, Kappos,L.,et al, 2004

Interferon beta-1b in Secondary Progressive MS
Neurol 63:1788-1795,1768, The North American Study Group on Interferon beta-, 2004

Acute Methotrexate Neurotoxicity: Findings on Diffusion-Weighted Imaging and Correlation with Clinical Outcome
AJNR 25:1688-1695, Rollins,N.,et al, 2004

Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003

Risk Factors for Fever in the Neurologic Intensive Care Unit
Neurol 60:837-841, Commichau,C.,et al, 2003

Validation of Diagnositc Magnetic Resonance Imaging Criteria for Multiple Sclerosis and Response to Interferon B1a
Ann Neurol 53:718-724, Barkhof,F.,et al, 2003

Neurotoxocity of Intrathecal Methotrexate: MR Imaging Findings
AJNR 24:1887-1890, Sandoval,C.,et al, 2003

Clinical Importance of Neutralising Antibodies Against Interferon Beta in Patients with Relapsing-Remitting Multiple Sclerosis
Lancet 362:1184-1191, Sorensen,P.S.,et al, 2003

Diffusion-Weighted MR Imaging of Pyogenic Ventriculitis
AJR 180:71-75, Pezzullo,J.A.,et al, 2003

Diffusion-Weighted Imaging and Apparent Diffusion Coefficient Maps in a Case of Intracerebral Abscess with Ventricular Extension
AJNR 23:109-112, Rana,S.,et al, 2002

Asymptomatic Choroid Plexus Cysts in the Lateral Ventricles: An Incidental Finding on Diffusion-Weighted MRI
Neuroradiology 44:830-833, Cakir,B.,et al, 2002

Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002

A Randomized, Double-Blind, Dose-Comparison Study of Weekly Interferon B-1a in Relapsing MS
Neurol 59:1507-1517,1482, Clanet,M.,et al, 2002

Randomized, Comparative Study of Interferon B-1a Treatment Regimens in MS
Neurol 59:1496-1506,1482, Panitch,H.,et al, 2002

An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS
Neurol 58:314-317, Calabresi,P.A.,et al, 2002

Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002

Recombinant Interferon-a-induced Chorea and Frontal Subcortical Dementia
Neurol 58:328-330, Moulignier,A.,et al, 2002

Interferon Beta-1a for Early Multiple Sclerosis: CHAMPS Trial Subgroup Analyses
Ann Neurol 51:481-490, Beck,R.W.,et al, 2002

Practice Paramenter: Neuroimaging of the Neonate
Neurol 58:1726-1738, Ment,L.R.,et al, 2002